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ABSTRACT 
Bronchial hyperresponsiveness (BHR) and mucus overproduction are common in CF 
pulmonary disease and allergic reactions can be frequently observed in cystic fibrosis 
(CF) lung disease. However, the underlying pathophysiological mechanisms are far from 
being completely understood. Therefore the expression of the Th2 type cytokines 
interleukin (IL)-4, IL-9 and IL-13 in CF patients with allergy was compared to patients 
without allergy. Peripheral blood mononuclear cells (PBMC) samples from 9 allergic CF 
patients and 8 non-allergic CF patients were obtained. In situ hybridization and 
immunocytochemistry were performed to determine mRNA and protein expression of IL-
4, IL-9, and IL-13 in PBMC. PBMC from allergic CF patients expressed significantly 
more IL-13 mRNA and protein compared to non-allergic patients (p < 0.05). There was 
no significant difference for IL-4 and IL-9 between the two groups. In both groups IL-9 
mRNA and protein expression were significantly higher compared to IL-4 and IL-13 
expression (p < 0.05). These results suggest that IL-13 plays an important role in allergic 
disease in CF. Moreover, IL-9 may be important in CF disease whether allergy is present 
or not as it may contribute to BHR and mucus overproduction. 
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INTRODUCTION 
 
Lung disease in cystic fibrosis (CF) is 
characterized by ongoing inflammation 
causing destruction of lung parenchyma 
and loss of lung function (Davies et al., 
1996). Although chronic bacterial infection 
and exacerbation are important features of 
CF pulmonary disease, allergic reactions 
such as bronchial asthma or allergic 
bronchopulmonary aspergillosis (ABPA) 
can complicate diagnosis and treatment of 
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bacterial infections and exacerbations 
(Warnet et al., 1996; Greenberger, 2002). 
It is well known from allergic lung 
diseases that cytokines like interleukin 
(IL)-4, IL-9 and IL-13 are important 
mediators in BHR and mucus 
overproduction (Dabbagh et al., 1999; 
Louahed et al., 2000; Nicolaides et al., 
1997; Zhu et al., 1999; Wills-Karp et al., 
1998) but these cytokines have not been 
investigated thoroughly in cystic fibrosis. 
IL-4 has been studied in ABPA (Skov et 
al., 1999) and in CF patients with respect 
to chronic infection with Pseudomonas 
aeruginosa (Moser et al., 2000). Recently, 
IL-13 has been described to be increased in 
CF patients compared to normal controls 
(Hauber et al. 2003). Data about IL-9 is 
still lacking. Given the role of these 
cytokines in allergic disease, we sought to 
investigate their expression in CF patients 
with allergic features. 
 
PATIENTS AND METHODS 
 
Patients: 
This study was approved by the Montreal 
Chest Institute Research Ethics Board of 
the McGill University Health Centre. 
Patients were recruited from the CF 
outpatient clinic at the Montreal Chest 
Institute, Montreal, Quebec during a one-
year period. 17 patients with stable  disease 
were included in the study. Stable disease 
was defined as no significant change in 
FEV1 over the last year with no 
exacerbation requiring IV antibiotics in the 
last six months. The patients were divided 
into two groups : allergic and non-allergic. 
Allergy was defined as elevated serum IgE 
levels with more than one positive skin test 
to common allergens, and a history of 
allergic reactions. According to these 
criteria, nine (9) patients were classified as 
allergic, eight (8) as non-allergic. 
 
Isolation of peripheral blood mononuclear 
cells: 
10 ml of peripheral venous blood was 
obtained from each patient. Blood was 
processed immediately after being drawn 
from the patient. Blood was diluted 1:1 
with PBS (phosphate buffered saline) and 
peripheral mononuclear cells (PBMC) 
were separated over Ficoll Paque 
(Pharmacia). PBMCs were washed twice 
with PBS. Hemolysis was carried out to 
eliminate red blood cells. The percentage 
of lymphocytes in PBMCs in all patients 
from both groups was > 85% as 
determined by immunohistochemistry 
using anti-CD3 antibody (DAKO, 
Mississauga, ON; dilution 1:100; APAAP 
technique, see immunohistochemistry 
section for technical details). 
 
Cytospin preparation: 
Cytospins of PBMCs were prepared for 
immunocytochemistry (ICC) and in situ 
hybridization (ISH). Cytospins for ICC 
were fixed in acetone/methanol for 7 min, 
air dried and stored at -20ºC. Cytospins for 
ISH were fixed in 4% paraformaldehyde 
for 30 min, washed twice in PBS, dried at 
37ºC overnight and then stored at -80ºC. 
 
Probe preparation: 
Sulfur 35 (S35)-labeled complementary 
RNA probes coding for IL-4, IL-9 and IL-
13 mRNA were prepared from cDNA as 
previously described (Durham et al., 
1997). In brief, cDNA was inserted into 
expression vectors, linearized, and 
transcribed in vitro in the presence of S35-
UTP, T7, and SP6 polymerase in either 
direction to produce antisense 
(complementary) and sense probes 
(identical to mRNA). 
 
In situ hybridization: 
Cytospins were processed for in situ 
hybridization to identify cytokine mRNA, 
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according to the method of Hamid et al. 
(Hamid et al., 1991). Permeabilization and 
fixation was performed 0.1 M glycine, 
0.3% triton, proteinase K, 4% 
paraformaldehyde (5 to 20 min at room 
temperature), and autoradiography 
solutions containing 10 mM 
triethanolamide, N-ethylmalamide and 
0.01 M Iodo acetamide (10 to 20 min at 
room temperature). After permeabilization, 
sections were prehybridized with 50% 
formamide in 2x standard sodium citrate 
for 15 min at 37ºC. Hybridization was 
carried out overnight at 42ºC with the 
hybridization mixture containing the 
appropiate S35-labeled sense or antisense 
probe (0.75 x 106 cpm/slide). 
Posthybridization involved a series of 
washes in decreasing concentrations of 
saline-sodium citrate buffer (SSC) (three 
times 4xSSC, 2xSCC, 1xSCC, 0.5xSCC, 
0.1xSCC for 20 min) at 42ºC. Samples 
were washed with a ribonuclease solution 
for 20 min at 42ºC to remove any unbound 
RNA probes. Dehydraation was perfomed 
using increasing concentrations of ethanol 
with 0.3 M ammonium acetates (70%, 
90%, 100% for 10 min). Hybridization 
signal was detected with standard 
autoradiography with KODAK D19 
developer and KODAK rapid fixer. 
 
Immunohistochemistry: 
To detect IL-4, IL-9 and IL-13 proteins, 
immunostaining was performed using the 
alkaline phospatase-antialkaline 
phosphatase (APAAP) technique as 
previously described (Giaid et al., 1993). 
The antibodies used were anti-IL-4, anti-
IL-9 and anti-IL-13 (all by R&D Systems, 
Minneapolis, MN). Dilution of antibodies 
were as follows: anti-IL-4 1:20, anti-IL-9 
1:50, anti-IL-13 1:20. Unspecific binding 
site were blocked by applying universal 
blocking solution (DAKO, Mississauga, 
ON) to the slides. After that sections were 
incubated with primary antibodies at 4ºC 
overnight, washed, and treated with rabbit 
anti-mouse antibody or rabbit anti-goat 
antibody (for IL-9) for 30 minutes at room 
temperature (dilution 1:30). The antibody-
antigen complex was developed with the 
alkaline phosphatase-anti-alkaline 
phosphatase complex or biotin-streptavidin 
complex (for IL-9) (dilution 1:30) and Fast 
Red (Sigma Chemical Co., Canada). 
Isotype controls were performed for every 
set of experiments. 
 
Quantification and statistical analysis: 
All slides were read in a blinded fashion- 
At least 200 cells were counted per slide. 
Percentages of positive cells of total cells 
were calculated. Percentages of IL-4, IL-9 
and IL-13 positive cells between allergic 
and non-allergic patients were compared 
using the nonparametric Kruskal-Wallis 
test. Statistically significant differences 
were subsequently analyzed with the 
Mann-Whitney U test (Systat version 7.0; 
SPSS, Chicago, Ill). A p value of less than 
0.05 was considered statistically 
significant. Values are given as 
mean±SEM if not otherwise stated. 
 
RESULTS 
 
Patient demographics: 
Table 1 summarizes the characteristics of 
the two patient groups. 
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Table 1: Characteristics of the patient groups 
 
     Allergic  Non-allergic 
     N = 9   N = 8   P  
Gender (male/female ratio) 3/6   4/4   n. s. 
Age (years)*    31.0±2.4  28.1±3.6  n. s. 
FVC (% predicted)*   73.1±7.5  81.5±8.1  n. s. 
FEV1 (% predicted)*  51.9±6.0  64.1±9.0  n. s. 
IgE (U/ml)^    86.8   37.3   < 0.05 
Psd. ae. colonization#   8/1   7/1  
 n. s. 
 
*; mean±SEM. ^: median value. Pse. ae.: Pseudomonas aeruginosa. #: 
positive/negative sputum culture. N. s.: not significant. 
 
IL-4, IL-9 and IL-13 expression in PBMC 
of allergic and non-allergic CF patients: 
 
There was no significant difference in the 
percentage of IL-4 mRNA positive and IL-
4 immunoreactive cells in allergic 
(0.76±0.21% and 0.06±0.07%) compared 
to non-allergic patients (0.78±0.25% and 
0.01±0.01%; both p > 0.05; Table 2). 
However, PBMC from allergic patients 
showed a significantly higher percentage 
of IL-13 mRNA and protein positive cells 
(2.98±0.63% and 1.96±0.66%) compared 
to those from non-allergic patients 
(1.33±0.24% and 0.62±0.25%; both p < 
0.05; Figures 1-2; Table 2). The 
percentage of PBMC positive cells for IL-9 
mRNA and IL-9 protein from allergic 
patients (5.90±0.82% and 4.10±1.02%) did 
not differ significantly from those from 
non-allergic patients (5.48±1.07% and 
4.09±1.96%; both p > 0.05; Figures 1-2; 
Table 2). In both patient groups, IL-9 
mRNA and protein expression was 
significantly higher than IL-4 and IL-13 
expression (p < 0.05). Table 2 summarizes 
these results. 
 
Table 2: mRNA and protein expression of Th2 type cytokines in PBMC of 
allergic and non-allergic CF patients 
 
   Allergic  Non-allergic  P 
IL-4 mRNA  0.76±0.21  0.78±0.25  n. s. 
IL-4 protein  0.06±0.07  0.01±0.01  n. s. 
IL-13 mRNA  2.98±0.63  1.33±0.24  < 0.05 
IL-13 protein  1.96±0.66  0.62±0.25  < 0.05 
IL-9 mRNA  5.90±0.82  5.48±1.07  n. s. 
IL-9 protein  4.10±1.02  4.09±1.96  n. s. 
 
Mean percentage of positive cells±SEM. N. s.: not significant. 
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Figure 1: Expression of IL-4, IL-13, and IL-9 mRNA in PBMC of allergic and non-allergic 
CF patients. Mean values±SEM are shown. *: p < 0.05 vs non-allergic. +: p < 0.05 vs IL-
4/IL-13. 
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Figure 2: Expression of IL-4, IL-13, and IL-9 protein in PBMC of allergic and non-allergic 
CF patients. Mean values±SEM are shown. *: p < 0.05 vs non-allergic. +: p < 0.05 vs IL-
4/IL-13. 
 
DISCUSSION 
 
In the present study, we found increased 
IL-13 mRNA and protein expression in 
PBMCs of allergic CF patients in 
comparison to non-allergic patients with 
the same condition. However, there was no 
significant difference in the expression of 
the two other Th2-type cytokines 
investigated in this study between the two 
groups. Also, expression of IL-9 mRNA 
and protein was significantly increased 
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compared to IL-4 and IL-13 expression in 
allergic CF patients. 
 
We chose to compare allergic and non-
allergic CF patients to investigate whether 
Th2 type cytokines would be involved in 
allergic reactions often associated with 
increased mucus production and BHR. 
Interestingly, IL-4 and IL-9 both having 
been shown to increase mucus secretion 
(Dabbagh et al., 1999; Louahed et al., 
2000; Nicolaides et al., 1997) and being 
involved in BHR (Louahed et al., 2000; 
Nicolaides et al., 1997) were not expressed 
in higher amounts (by means of positive 
PBMC) in allergic CF patients, whereas a 
significantly higher proportion of IL-13-
positive PBMCs were observed. This 
finding suggests that allergic reactions may 
be mediated by IL-13 in CF. We did not 
investigate patients with ABPA as an 
example of a Th2-predominated immune 
response in CF patients (Greenberger, 
2002; Skov et al., 1999), but IL-13 may 
also play an important role in this 
condition. Our data is in agreement with a 
previous study demonstrating increased IL-
13 (but not IL-4) expression in CF patients 
compared to healthy controls (Hauber et 
al., 2003). 
 
In the present study we focused on 
cytokine mRNA and protein expression 
using in situ hybdridizazion and 
immunohistochemistry to get an idea of the 
numbers of PBMC expressing Th2 type 
cytokines. Although the numbers are 
relatively small these cells may have an 
effect by promoting allergic reactions. This 
notion is supported by the results from 
previous studies demonstrating increased 
expression of Th2 type cytokines in CF 
patients with chronic infection with 
Pseudomonas aeruginosa (Moser et al., 
2000; Hauber et al., 2003). 
 
It has been previously reported that PBMC 
of CF patients suffering from chronic 
infection with Pseudomonas aeruginosa 
produce more IL-4 compared to those 
PBMC of patients without chronic 
infection (Moser et al., 2000). In the 
present study, all patients except one of 
each group were chronically infected with 
Pseudomonas aeruginosa. Therefore, 
presence or absence of chronic infection 
with this bacteria should not be an 
important factor for differences in cytokine 
expression in the present study. However, 
we studied unstimulated PBMC whereas 
Moser et al. measured cytokine production 
from stimulated PBMCs (Moser et al., 
2000). It is possible that stimulation of 
PBMCs would reveal differences in IL-4 
or IL-9 expression in the patients studied 
here. However, unstimulated PBMCs may 
represent something closer to in vivo 
conditions. 
 
In comparison to IL-4 and IL-13, a 
significantly higher percentage of PBMCs 
expressed IL-9. This finding suggests that 
IL-9 may be involved in inflammatory 
reactions in CF regardless whether patients 
are allergic or not. IL-9 may contribute to 
BHR and mucus overproduction in CF 
lung disease as reported previously for 
other lung diseases (Nicolaides et al., 
1997). Moreover, a previous study found 
increased expression of IL-9 in upper 
airway mucosa of CF patients (Hauber et 
al., 2003). 
 
In conclusion, results from this study 
suggest that IL-13 plays an important role 
in allergic reactions in CF whereas IL-9 
may contribute to BHR and mucus 
hypersecretion in both allergic and non-
allergic CF patients. IL-4 may not be as 
important as other Th2 type cytokines in 
CF PBMCs although it has been detected 
in CF bronchial mucosa (Wojnarowski et 
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al., 1999). Further studies are warranted to 
better define Th2 type cytokine expression 
in CF lungs in order to evaluate 
inflammatory patterns of CF lung 
inflammation. 
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